Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis

J Int Med Res. May-Jun 2003;31(3):157-69. doi: 10.1177/147323000303100301.

Abstract

The efficacy and safety of a 5-day regimen of 800 mg telithromycin once daily was compared with a standard 10-day regimen of 500 mg cefuroxime axetil twice daily in a multicentre, randomized, double-blind, parallel-group trial involving 376 patients with acute exacerbations of chronic bronchitis (AECB). In clinically evaluable patients (n = 282), post-therapy clinical cure rates were 86.4% with telithromycin and 83.1% with cefuroxime axetil. In bacteriologically evaluable patients (n = 53), eradication or presumed eradication of the pathogen was achieved in 76.0% and 78.6% of telithromycin and cefuroxime axetil patients, respectively. Adverse events were mostly mild; the most common were diarrhoea (12.8% versus 11.8%) and nausea (8.9% versus 3.2%) in telithromycin and cefuroxime axetil patients, respectively. The 5-day regimen of 800 mg telithromycin once daily was similar in efficacy and equally well tolerated as a 10-day regimen of 500 mg cefuroxime axetil twice daily in adults with AECB.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Bronchitis, Chronic / drug therapy*
  • Cefuroxime / administration & dosage*
  • Cefuroxime / adverse effects
  • Cefuroxime / analogs & derivatives*
  • Female
  • Humans
  • Ketolides*
  • Macrolides / administration & dosage*
  • Macrolides / adverse effects
  • Male
  • Middle Aged
  • Prognosis
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Ketolides
  • Macrolides
  • telithromycin
  • Cefuroxime
  • cefuroxime axetil